Black Diamond Therapeutics (BDTX) Competitors

Arbutus Biopharma (NASDAQ:ABUS) and Black Diamond Therapeutics (NASDAQ:BDTX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, media sentiment, valuation, analyst recommendations, risk and institutional ownership.

Is ABUS or BDTX more profitable?

Black Diamond Therapeutics has a net margin of 0.00% compared to Arbutus Biopharma's net margin of -352.24%. Black Diamond Therapeutics' return on equity of 12.70% beat Arbutus Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arbutus Biopharma	-352.24%	-59.28%	-44.11%
Black Diamond Therapeutics	N/A	12.70%	9.58%

Does the media refer more to ABUS or BDTX?

In the previous week, Black Diamond Therapeutics had 11 more articles in the media than Arbutus Biopharma. MarketBeat recorded 17 mentions for Black Diamond Therapeutics and 6 mentions for Arbutus Biopharma. Black Diamond Therapeutics' average media sentiment score of 0.91 beat Arbutus Biopharma's score of 0.43 indicating that Black Diamond Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arbutus Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Black Diamond Therapeutics	6 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts prefer ABUS or BDTX?

Arbutus Biopharma presently has a consensus target price of $5.50, suggesting a potential upside of 63.20%. Black Diamond Therapeutics has a consensus target price of $12.40, suggesting a potential upside of 344.44%. Given Black Diamond Therapeutics' higher possible upside, analysts clearly believe Black Diamond Therapeutics is more favorable than Arbutus Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arbutus Biopharma	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00
Black Diamond Therapeutics	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has stronger earnings and valuation, ABUS or BDTX?

Black Diamond Therapeutics has lower revenue, but higher earnings than Arbutus Biopharma. Arbutus Biopharma is trading at a lower price-to-earnings ratio than Black Diamond Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arbutus Biopharma	$6.17M	104.70	-$69.92M	-$0.29	-11.62
Black Diamond Therapeutics	N/A	N/A	-$69.68M	$0.23	12.13

Which has more risk and volatility, ABUS or BDTX?

Arbutus Biopharma has a beta of 0.86, meaning that its stock price is 14% less volatile than the S&P 500. Comparatively, Black Diamond Therapeutics has a beta of 2.87, meaning that its stock price is 187% more volatile than the S&P 500.

Do institutionals and insiders have more ownership in ABUS or BDTX?

43.8% of Arbutus Biopharma shares are held by institutional investors. Comparatively, 95.5% of Black Diamond Therapeutics shares are held by institutional investors. 20.3% of Arbutus Biopharma shares are held by insiders. Comparatively, 6.0% of Black Diamond Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Black Diamond Therapeutics beats Arbutus Biopharma on 12 of the 14 factors compared between the two stocks.